Eli Lilly and Company $LLY Shares Purchased by WD Rutherford LLC

WD Rutherford LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 17.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 4,410 shares of the company’s stock after buying an additional 664 shares during the quarter. Eli Lilly and Company accounts for 1.9% of WD Rutherford LLC’s investment portfolio, making the stock its 16th biggest holding. WD Rutherford LLC’s holdings in Eli Lilly and Company were worth $5,103,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Verde Servicos Internacionais S.A. increased its holdings in shares of Eli Lilly and Company by 0.6% in the 3rd quarter. Verde Servicos Internacionais S.A. now owns 8,048 shares of the company’s stock valued at $9,312,000 after purchasing an additional 48 shares during the period. Penobscot Investment Management Company Inc. boosted its holdings in shares of Eli Lilly and Company by 14.4% during the third quarter. Penobscot Investment Management Company Inc. now owns 14,451 shares of the company’s stock worth $16,721,000 after purchasing an additional 1,817 shares during the period. Cahaba Wealth Management Inc. grew its position in Eli Lilly and Company by 3.4% during the third quarter. Cahaba Wealth Management Inc. now owns 1,428 shares of the company’s stock valued at $1,652,000 after purchasing an additional 47 shares in the last quarter. Oppenheimer & Co. Inc. grew its position in Eli Lilly and Company by 10.5% during the third quarter. Oppenheimer & Co. Inc. now owns 86,953 shares of the company’s stock valued at $100,612,000 after purchasing an additional 8,271 shares in the last quarter. Finally, Park Avenue Securities LLC increased its stake in Eli Lilly and Company by 4.7% in the 3rd quarter. Park Avenue Securities LLC now owns 37,258 shares of the company’s stock valued at $43,110,000 after buying an additional 1,656 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last 90 days. 0.14% of the stock is owned by insiders.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong earnings and sales beat estimates. Third-quarter revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the roughly $5.68 analyst consensus. Reported EPS was $7.22, up from $6.21 a year earlier. Eli Lilly earnings report
• Positive Sentiment: Demand for GLP-1 drugs continues to accelerate. Mounjaro sales increased 65% to $10.7 billion, while Zepbound revenue climbed 49% to $5.35 billion. The performance reinforced expectations that Lilly can continue gaining share in the rapidly expanding diabetes and obesity markets. Eli Lilly stock jumps on Mounjaro and Zepbound earnings
• Positive Sentiment: Management sharply increased its outlook. Lilly raised 2026 revenue guidance to $91 billion-$92 billion from $85 billion-$87 billion, lifting the midpoint by $5.5 billion. The company also highlighted regulatory progress, including Mounjaro’s cardiovascular-risk indication and approval of once-weekly insulin Onswik. Eli Lilly raises revenue outlook
• Positive Sentiment: Pipeline momentum added to investor enthusiasm. Phase 3 data showed experimental retatrutide produced greater A1C reductions and more than double the weight loss of Ozempic 2 mg in adults with type 2 diabetes, strengthening Lilly’s competitive position against Novo Nordisk. Retatrutide trial results
• Neutral Sentiment: Investors should monitor the quality and durability of growth. Realized prices declined about 15%, although a 53% volume increase more than offset the pressure. Approximately $900 million of quarterly benefits came from Jardiance milestones and rebate adjustments, neither of which is expected to recur fully.
• Negative Sentiment: One-time deal-related charges and access concerns remain risks. Lilly recorded about $4.2 billion in acquired in-process R&D charges, while reports also noted a Foundayo sales miss and potential employer concerns about covering costly weight-loss drugs. These factors could pressure margins or slow future demand. Eli Lilly pricing and earnings reaction

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Sanford C. Bernstein reiterated an “outperform” rating and issued a $1,450.00 target price on shares of Eli Lilly and Company in a research report on Monday. TD Cowen restated a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Wall Street Zen downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Saturday, October 17th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Finally, Truist Financial increased their price objective on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,320.25.

Eli Lilly and Company Stock Up 6.5%

Shares of Eli Lilly and Company stock opened at $1,372.01 on Friday. The firm has a market cap of $1.29 trillion, a price-to-earnings ratio of 46.04, a P/E/G ratio of 1.73 and a beta of 0.46. The stock has a 50-day simple moving average of $1,194.34 and a 200-day simple moving average of $1,090.89. Eli Lilly and Company has a 52-week low of $812.25 and a 52-week high of $1,408.38. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.68 by $1.80. The firm had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The firm’s revenue was up 38.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $7.02 earnings per share. On average, equities research analysts expect that Eli Lilly and Company will post 33.22 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s payout ratio is currently 23.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.